Trinity Biotech PLC
NASDAQ:TRIB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IE |
|
Trinity Biotech PLC
NASDAQ:TRIB
|
13.5m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
201.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
125B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
113.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.6B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -37.7% |
| 30th Percentile | 19.3% |
| Median | 32% |
| 70th Percentile | 38.1% |
| Max | 1 012% |
Other Profitability Ratios
Trinity Biotech PLC
Glance View
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Trinity Biotech PLC is 33.8%, which is above its 3-year median of 32.9%.
Over the last 3 years, Trinity Biotech PLC’s Gross Margin has decreased from 38% to 33.8%. During this period, it reached a low of 26.6% on Sep 30, 2022 and a high of 38% on Jun 30, 2022.
